Eupraxia Pharmaceuticals Stock Target Price
| EPRX Stock | CAD 7.21 0.44 5.75% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Eupraxia Pharmaceuticals' long-term financial health and intrinsic value.
Eupraxia | Target Price |
Eupraxia Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eupraxia Pharmaceuticals' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eupraxia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics of similar companies.Eupraxia Pharmaceuticals is currently under evaluation in target price category among its peers.
Eupraxia Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Eupraxia Pharmaceuticals from analyzing Eupraxia Pharmaceuticals' financial statements. These drivers represent accounts that assess Eupraxia Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Eupraxia Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 101.4M | 23.6M | 56.2M | 73.3M | 84.3M | 83.4M |
Eupraxia Fundamentals
| Return On Equity | -1.17 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 280.16 M | ||||
| Shares Outstanding | 35.85 M | ||||
| Shares Owned By Insiders | 19.12 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 612 | ||||
| Price To Book | 82.33 X | ||||
| EBITDA | (27.32 M) | ||||
| Net Income | (25.74 M) | ||||
| Cash And Equivalents | 35.46 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 1.54 M | ||||
| Debt To Equity | 0.42 % | ||||
| Current Ratio | 10.13 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (29.99 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (1.04) X | ||||
| Target Price | 12.5 | ||||
| Number Of Employees | 33 | ||||
| Beta | 1.55 | ||||
| Market Capitalization | 274.25 M | ||||
| Total Asset | 34.94 M | ||||
| Retained Earnings | (131 M) | ||||
| Working Capital | 31.33 M | ||||
| Net Asset | 34.94 M |
About Eupraxia Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eupraxia Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eupraxia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eupraxia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Eupraxia Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eupraxia Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eupraxia Stock
| 0.87 | JPM | JPMorgan Chase | PairCorr |
| 0.77 | BOFA | Bank of America | PairCorr |
| 0.87 | CITI | CITIGROUP CDR | PairCorr |
| 0.73 | RY | Royal Bank | PairCorr |
| 0.83 | TD | Toronto Dominion Bank | PairCorr |
Moving against Eupraxia Stock
The ability to find closely correlated positions to Eupraxia Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eupraxia Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eupraxia Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eupraxia Pharmaceuticals to buy it.
The correlation of Eupraxia Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eupraxia Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eupraxia Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eupraxia Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Eupraxia Stock
Eupraxia Pharmaceuticals financial ratios help investors to determine whether Eupraxia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eupraxia with respect to the benefits of owning Eupraxia Pharmaceuticals security.